Cerdelga
Named-patient access overview. Cerdelga is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Cerdelga (eliglustat) is Sanofi's oral substrate reduction therapy for Gaucher disease type 1. It is the first oral therapy approved as a first-line option for Gaucher type 1 in adults whose CYP2D6 metabolizer status (extensive, intermediate, or poor) places them in the labeled population. For Saudi Arabia families with a confirmed Gaucher type 1 diagnosis and a documented CYP2D6 genotype, this page describes the SFDA Personal Importation Program pathway.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Cerdelga
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Cerdelga is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Cerdelga in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Cerdelga
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.